<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148186</url>
  </required_header>
  <id_info>
    <org_study_id>CIHR-2009MOP-201314-KTE</org_study_id>
    <nct_id>NCT01148186</nct_id>
  </id_info>
  <brief_title>An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults</brief_title>
  <official_title>The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An educational intervention targeting community-dwelling older adults will lead to a
      reduction in potentially inappropriate prescriptions (e.g. benzodiazepines, oxybutynin).

      Cessation of potentially inappropriate medications (e.g. benzodiazepines, oxybutynin)will
      lead to improved cognitive outcomes in older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study tests the effectiveness of a knowledge transfer tool for empowering patients to
      engage in collaborative discontinuation of potentially inappropriate medication with their
      pharmacist and/or physician
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study funding period reached conclusion. Sample size sufficient to complete the analysis on
    benzodiazepines.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete discontinuation of the targeted potentially inappropriate medication (e.g. benzodiazepines, oxybutynin)</measure>
    <time_frame>6 months post-intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>6-months post-intervention</time_frame>
    <description>Montreal cognitive assessment instrument Rey`s auditory verbal learning test (immediate memory, learning, and delayed recall)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep efficiency</measure>
    <time_frame>6-months</time_frame>
    <description>Sleep efficiency as documented with a sleep diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incontinence-related self-efficacy</measure>
    <time_frame>6-months post-intervention</time_frame>
    <description>incontinence-related self-efficacy as measured with the geriatric self-efficacy index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of urinary incontinence episodes</measure>
    <time_frame>6-months post-intervention</time_frame>
    <description>frequency of urinary incontinence as measured with a 72-hour bladder diary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Polypharmacy</condition>
  <condition>Incontinence</condition>
  <condition>Insomnia</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Educational intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-list group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>knowledge transfer tool</intervention_name>
    <description>knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician</description>
    <arm_group_label>Educational intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65 year old human adults

          -  who fill a prescription for at least 5 medications

          -  community dwelling

          -  chronic use (3 months or longer) of at least one potentially inappropriate medication
             (e.g. benzodiazepine, oxybutynin)

        Exclusion Criteria:

          -  patients with severe mental illness, dementia and epilepsy

          -  concomitant consumption of any other antipsychotic medication (including lithium,
             olanzapine, clozapine, quetiapine, risperidone, haloperidol etc.)

          -  concomitant consumption of any antiepileptic (including carbamazepine, valproate,
             gabapentin, lamotrigine, topiramate, oxcarbazepine etc.)

          -  concomitant consumption of a cholinesterase inhibitor or memantine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cara Tannenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche de l'Institut universitaire de gériatrie de Montréal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Le Groupe Jean Coutu Inc.</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4G 1S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal</investigator_affiliation>
    <investigator_full_name>Cara Tannenbaum</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Polypharmacy</keyword>
  <keyword>Benzodiazepine use</keyword>
  <keyword>Oxybutynin use</keyword>
  <keyword>cognition disorders/drug therapy</keyword>
  <keyword>incontinence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

